文献速递糖尿病

GRADE研究:2型糖尿病联合治疗中的用药依从性分析

Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
PubMed 文献 · Diabetes Care · 2026-01-01

GRADE子研究纳入1739例单用二甲双胍的2型糖尿病患者,随机加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀,每半年用三条目量表评估依从性共3年。总体依从性高(88.7±10.01),3年内略降;3年时格列美脲和西格列汀组依从性分别比利拉鲁肽组高5%和3%。依从性每降10分,主要和次要血糖结局风险分别增加15%和19%。

要点

  • GRADE子研究中总体用药依从性高,3年平均88.7分(0-100量表)。
  • 依从性每降10分,HbA1c≥7.0%和>7.5%风险分别增15%和19%。
  • 治疗组间依从性差异小且临床意义不明确,需持续评估依从性。

核心结论

  • GRADE研究中用药依从性持续较高,治疗组间差异小且临床意义不明确。
  • 总体而言,较低依从性稳健预测血糖控制恶化,强调持续评估的重要性。

研究设计与样本

  • GRADE子研究纳入1739例2型糖尿病病程<10年、HbA1c 6.8%-8.5%、单用二甲双胍的参与者。
  • 随机加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀,每半年用验证的三条目量表(0-100)评估依从性共3年。

主要发现

  • 3年总体平均依从性为88.7±10.01(0-100量表),较基线略降(-2.0±14.7;P<0.0001)。
  • 3年时格列美脲和西格列汀组依从性分别比利拉鲁肽组高5%和3%(均P<0.05)。
  • 依从性每降10分,主要结局(HbA1c≥7.0%)风险增15%,次要结局(HbA1c>7.5%)风险增19%(均P<0.0001)。
  • 在甘精胰岛素或利拉鲁肽组,较低依从性对次要结局的预测略强于格列美脲或西格列汀组(各P<0.05)。

关键数值与推荐

  • 依从性量表评分范围0-100,分数越高依从性越好。
  • 主要血糖结局定义为HbA1c≥7.0%,次要结局定义为HbA1c>7.5%。

临床怎么用

  • 临床应持续评估2型糖尿病患者的用药依从性,因其与血糖控制恶化稳健相关。
  • 不同降糖药物间依从性差异较小,选择药物时依从性不应作为主要区分因素。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To address previous inconsistencies in reports of differential adherence to diabetes medications, we examined medication adherence and evaluated treatment group differences in a substudy of participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: GRADE participants (type 2 diabetes duration <10 years, HbA1c 6.8%-8.5%, on metformin alone) were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739). Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes. RESULTS: Overall mean ± SD adherence (average of participant-level mean ± SD) was high over 3 years of follow-up at 88.7 ± 10.01, on a scale of 0-100, and decreased slightly by 3 years relative to baseline (-2.0 ± 14.7; P < 0.0001). No intergroup differences were observed until 3 years, when adherence was 5% and 3% higher for the glimepiride and sitagliptin groups, respectively, than for liraglutide (both P < 0.05). Over follow-up and across groups, a 10-point decrease in adherence was associated with 15% and 19% increased risk of reaching primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes (both P < 0.0001). Lower adherence was somewhat more predictive of the secondary outcome for those assigned to glargine or liraglutide, compared with glimepiride or sitagliptin (each P < 0.05). No other comparisons were significant. CONCLUSIONS: Medication adherence was consistently high in GRADE. Observed treatment group differences were small and of unclear clinical significance. Overall, lower adherence robustly predicted worsening glycemic control, highlighting the importance of ongoing assessment.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Gonzalez JS, Wen H, Butera NM, et al. Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026. PMID: 41557987. doi:10.2337/dc25-2008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。